Merck KGaA Boosts Stock With Job Cuts Amid Drug Drought

The next drug approval for Merck KGaA, Germany’s second-biggest drugmaker, probably won’t come until 2016, more than a decade after the blockbuster cancer treatment Erbitux reached the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.